维奈克拉联合方案在初诊不适合强化疗急性髓系白血病常规实践中的疗效与安全性
该回顾性研究评估了维奈克拉联合去甲基化药物或低剂量阿糖胞苷在临床试验外治疗初诊不适合强化疗AML患者的疗效与安全性。结果显示CR+CRi率达61%,应答者中位EFS为11.7个月,全队列中位OS为9.8个月,继发性AML与HMA经治患者CR+CRi率分别为61%和43%。治疗耐受性良好,TLS发生率为12%。
要点
- 维奈克拉联合方案在常规实践中CR+CRi率达61%,继发性AML与初发AML获益相似。
- 应答患者中位EFS为11.7个月,全队列中位OS为9.8个月。
- 不良核型是CR/CRi的唯一负性预测因素,ECOG PS与不良核型均与更短OS相关。
核心结论
- 维奈克拉联合方案在初诊不适合强化疗的AML患者中显示出与临床试验相似的疗效和安全性。
- 继发性AML患者可从维奈克拉联合方案中获得与初发AML相似的获益。
- 达到CR/CRi并接受异基因造血干细胞移植的患者中位OS更高。
研究设计与样本
- 回顾性报告临床试验外接受维奈克拉联合去甲基化药物或低剂量阿糖胞苷治疗的初诊不适合强化疗AML患者。
主要发现
- CR+CRi率为61%,继发性AML和HMA经治患者的CR+CRi率分别为61%和43%。
- 应答患者中复发率为25%,中位EFS为11.7个月(95% CI 10.09-13.35)。
- 中位随访8.7个月时,全队列中位OS为9.8个月(95% CI 6.42-13.3)。
- 多因素分析显示不良核型是CR/CRi的唯一负性预测因素(p=.03),ECOG PS和不良核型均与更短OS显著相关(p=.023和.038)。
- TLS发生率为12%,副作用与随机临床试验中描述相似。
临床怎么用
- 维奈克拉联合HMA或LDAC可用于初诊不适合强化疗的AML患者,包括继发性AML。
- 对达到CR/CRi的选定患者可考虑接受异基因造血干细胞移植。
- 治疗期间需监测肿瘤溶解综合征,本研究中发生率为12%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combinations of the BCL-2 inhibitor, venetoclax, with either hypomethylating agents (HMA) or low dose cytarabine (LDAC), have shown promising results in clinical trials of AML patients unfit for intensive therapy. We report on the efficacy and safety of venetoclax combinations in AML patients treated outside of clinical trials. Complete remission (CR) + CR with incomplete count recovery (CRi) were achieved in 61% of patients, with similar CR+CRi rates in with secondary AML, and in patients who were previously treated with HMA (61% and 43%, respectively). Relapse occurred in 25% of patients, with a median event-free survival (EFS) of 11.7 months (95% CI, 10.09-13.35) in responding patients. At a median follow up of 8.7 months, the median overall survival (OS) was 9.8 months (95% CI 6.42-13.3) in the entire cohort. In multivariate analysis adverse karyotype was the only negative predictor of CR/CRi (p = .03), while both ECOG performance status (PS) and adverse karyotype were significantly associated with shorter OS (p = .023 and .038, respectively). Median OS was higher in patients achieving CR/CRi and in patients proceeding to allogeneic stem cell transplantation (allo-SCT). Treatment was well tolerated, with side effects similar to those described in the randomized clinical trials. Tumor lysis syndrome (TLS) occurred in 12% of patients. Our data support the efficacy and safety of venetoclax combinations in newly diagnosed AML patients not eligible for intensive therapy. According to our data, secondary AML patients could benefit from venetoclax combinations similarly to de-novo AML patients, and allo-SCT could be offered to selected patients achieving CR/CRi.
引用
- Apel A, Moshe Y, Ofran Y, et al. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021. PMID: 33836555. doi:10.1002/ajh.26190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。